First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT07284186. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, First-in-Human Study of the SMARCA2 Degrader, PLX-61639, in Patients With SMARCA4-Mutated Locally Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT07284186
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Plexium, Inc.
- Industry
- Enrollment
- 155 participants
Conditions and interventions
Conditions
- Advanced Solid Tumor
- Esophageal Adenocarcinoma
- Esophageal Squamous Cell Carcinoma
- Gastric Adenocarcinoma
- Gastric Squamous Cell Carcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastroesophageal Junction Squamous Cell Carcinoma
- Metastatic Solid Tumor
- Non-Small Cell Lung Carcinoma
- SMARCA4 Mutation
Interventions
- PLX-61639 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2025
- Primary completion
- Nov 30, 2029
- Completion
- Aug 31, 2030
- Last update posted
- Apr 12, 2026
2025 – 2030
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Scottsdale | Arizona | 85258 | Recruiting |
| Research Site | Duarte | California | 91010 | Not yet recruiting |
| Research Site | Orange | California | 92868 | Not yet recruiting |
| Research Site | Boston | Massachusetts | 02114 | Not yet recruiting |
| Research Site | St Louis | Missouri | 63110 | Recruiting |
| Research Site | New York | New York | 10044 | Recruiting |
| Research Site | Durham | North Carolina | 27710 | Recruiting |
| Research Site | Cleveland | Ohio | 44106 | Recruiting |
| Research Site | San Antonio | Texas | 78229 | Recruiting |
| Research Site | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07284186, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07284186 live on ClinicalTrials.gov.